Mgi Tech Co.,Ltd. (688114.SH) hit the daily trading limit shortly after the market opened, with shares climbing 20% to 69.11 yuan and turnover reaching 428 million yuan. This sharp rally follows a major breakthrough in the global mRNA tumor vaccine sector, as Moderna and Merck's personalized mRNA cancer vaccine succeeded in a large-scale Phase III clinical trial.

The vaccine approach requires surgeons to remove a patient's tumor, extract a sample for gene sequencing, and then design a customized vaccine targeting the specific genetic mutation "fingerprint" unique to each patient's cancer. Without precise sequencing analysis, identifying the exclusive target becomes impossible, making the vaccine design process unviable. This underscores a strategic revaluation of gene sequencing as the "underlying infrastructure" for personalized tumor vaccines.

Public records show that Mgi Tech Co.,Ltd. is a leading domestic gene sequencing company. Leveraging its independently developed sequencing hardware and technology platforms, the company has consistently driven down the cost of gene sequencing, freeing high-throughput tumor sequencing from prohibitive expenses. This solidifies the foundational technology base for moving individualized mRNA cancer vaccines from research concepts to large-scale clinical application, potentially making these innovative therapies more accessible and affordable for broader patient populations.

The success of Moderna's Phase III tumor vaccine trial has accelerated the entire industry, positioning gene sequencing for a historic opportunity in clinical adoption.